Wellington Management Group LLP Has $2.14 Million Position in DaVita Inc. $DVA

Wellington Management Group LLP boosted its stake in DaVita Inc. (NYSE:DVA) by 305.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,610 shares of the company’s stock after acquiring an additional 7,238 shares during the period. Wellington Management Group LLP’s holdings in DaVita were worth $2,138,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Berkshire Hathaway Inc acquired a new stake in DaVita during the second quarter worth approximately $6,425,269,000. BlackRock Inc. purchased a new stake in DaVita in the 2nd quarter valued at $547,520,000. Bank of America Corp DE purchased a new stake in DaVita in the 2nd quarter valued at about $145,057,000. Arrowstreet Capital Limited Partnership boosted its position in DaVita by 114.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock worth $135,196,000 after purchasing an additional 636,191 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in DaVita in the second quarter valued at about $101,127,000. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Barclays lifted their target price on shares of DaVita from $218.00 to $224.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 5th. UBS Group raised their price target on DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a report on Friday, July 10th. Truist Financial cut their target price on shares of DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a research report on Friday, August 7th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $265.00 target price on shares of DaVita in a research note on Wednesday, August 5th. Finally, Weiss Ratings raised DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 5th. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $233.43.

Insiders Place Their Bets

In related news, insider Kathleen Waters sold 15,405 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $208.40, for a total value of $3,210,402.00. Following the sale, the insider owned 109,194 shares in the company, valued at approximately $22,756,029.60. This trade represents a 12.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.90% of the stock is currently owned by company insiders.

DaVita Trading Down 0.9%

DVA opened at $181.36 on Friday. DaVita Inc. has a 12-month low of $101.00 and a 12-month high of $247.49. The company has a market cap of $11.57 billion, a price-to-earnings ratio of 14.84, a price-to-earnings-growth ratio of 0.47 and a beta of 0.83. The stock has a fifty day simple moving average of $205.09 and a two-hundred day simple moving average of $185.46.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, beating analysts’ consensus estimates of $3.88 by $0.14. The company had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.50 billion. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the company earned $2.95 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, analysts predict that DaVita Inc. will post 14.57 EPS for the current year.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a healthcare company focused primarily on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis services for people with chronic kidney failure, including in-center hemodialysis and home-based dialysis options. Its services also include clinical care, education, nutrition support and other resources intended to help patients manage kidney disease.

DaVita also provides broader kidney-care services, including chronic kidney disease management, care coordination and support for patients who may be candidates for kidney transplantation.